14 July 2017 - - In 2017, the global malignant mesothelioma market is expected to reach a value of USD 338m. By the end of 2025, the global market for malignant mesothelioma is anticipated to have soared at 7.5% CAGR, reaching an estimated USD 604m in value, according to a report from third-platform research firm Persistence Market Research.

The global malignant mesothelioma market is expected to incur favourable boost from increased healthcare spending witnessed in multiple parts of the world, coupled with availability of better treatment prognosis for mesothelioma.

The report observes that increasing use of asbestos for commercial purposes is fuelling the incidence of malignant mesothelioma among people.

Studies focused on the cause of malignant mesothelioma are being publicised to boost awareness.

Through such work, people are becoming more aware, particularly with respect to association of the HOXB4 gene in stopping the maturation of mesothelioma tumor.

Overall, the global market for malignant mesothelioma is also witnessing an increased adoption of combination therapies.

Many companies are promoting the cumulative use of chemotherapy and immune-oncology procedures in treatment of malignant mesothelioma.

In addition to this, malignant mesothelioma is gaining incidence among men. Exposure to asbestos is likely to remain concentrated to male demographics of the world.

Increased exposure to such toxic elements is aggravating the incidence of mesothelioma in men.

Key players in the global malignant mesothelioma market are also collaborating with leading research organizations to develop combination drugs on mesothelioma, the approval of which is drawing highest regard of authorities such as the FDA.

Leading players in the global malignant mesothelioma market include Sanofi, Eli Lilly and company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd., Corden Pharma International GmbH, Concordia International Corp., Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd., Nichi-Iko Pharmaceutical Co., Ltd., AstraZeneca Plc., Bristol-Myers Squibb company, F. Hoffmann-La Roche Ltd., Merck and Co., Inc., Novartis AG, and Pfizer Inc.

Demand for malignant mesothelioma treatment is expected to be high in the Asia-Pacific (APAC) region. Higher exposure to asbestos across APAC industries is driving this demand as the region is anticipated to record fastest growth at 8% CAGR.

Pemetrexed drugs are gaining traction, globally, sales of which are expected to account for more than 45% revenue share through 2025.
Throughout the forecast period, revenues accounted by parenteral administration of malignant mesothelioma drugs is expected to be over 90% of global market revenues.

The report also projects that hospital pharmacies will be largest distribution channel in the global malignant mesothelioma market, accounting for around 50% of global sales at any point of the forecast period.